Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab in collagenous gastritis
NCT06317220Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2024
- Primary completion
- Feb 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vedolizumab in collagenous gastritis (CG), sponsored by Massachusetts General Hospital. Started Dec 2024; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
collagenous gastritis (CG)
Beyond the preview
Go deeper on NCT06317220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06317220.